GERN
GERON CORP
- Latest sale
- $19k
- Feb 18 · Unusual
- Form 4 sales
- 93
- On record
- Form 144 notices
- 2
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleRoutineMay 11 2023
Sold 35,000 shares at $3.00 ($105k)
Lawlis V Bryan, Director
10b5-1 planSold 100% of holdings ($105k position)0 shares leftFirst sale on recordFollows a Form 144Filing
- 2 Form 144 noticeNoticeMay 11 same day
Filed to sell 35,000 shares ($105k)
Lawlis V Bryan, Director
10b5-1 planFirst sale on recordFiling
- 3 Form 4 saleRoutineMay 15 +370 days
Sold 35,000 shares at $3.75 ($131k)
Lawlis V Bryan, Director
10b5-1 planSold 100% of holdings ($131k position)0 shares leftFiling
- 4 Form 4 saleUnusualJun 4 +20 days
Sold 600,000 shares at $4.00 ($2.4M)
Scarlett John A, Chairman, President and CEO
No 10b5-1 planSold 50% of holdings ($4.8M position)600,000 shares leftFiling
- 5 Form 4 saleUnusualJun 10 +6 days
Sold 421,875 shares at $4.65 ($2M)
Kapur Anil, EVP, Corp Strategy & CCO
No 10b5-1 planSold 100% of holdings ($2M position)0 shares leftFirst sale on recordFiling
- 6 Form 4 saleUnusualJun 10 same day
Sold 287,900 shares at $4.63 ($1.3M)
Feller Faye, EVP, Chief Medical Officer
No 10b5-1 planSold 100% of holdings ($1.3M position)0 shares leftFirst sale on recordFiling
- 7 Form 4 saleUnusualJul 8 +28 days
Sold 674,348 shares at $4.56 ($3.1M)
Grethlein Andrew J, EVP, Chief Operating Officer
No 10b5-1 planSold 100% of holdings ($3.1M position)0 shares leftFiling
- 8 Form 4 saleUnusualFeb 18 +590 days
Sold 9,855 shares at $1.94 ($19k)
Robertson Michelle, EVP, CHIEF FINANCIAL OFFICER
No 10b5-1 planSold 35.8% of holdings ($53k position)17,645 shares leftFirst sale on recordFiling
Every transaction
Loading transactions…
Sales, notices and lockups (95)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | Robertson Michelle | EVP, CHIEF FINANCIAL OFFICER | Form 4 sale | 9,855 | $19k | 35.8% | Unusual | SEC |
| Jul 8, 2024 | Grethlein Andrew J | EVP, Chief Operating Officer | Form 4 sale | 674,348 | $3.1M | 100.0% | Unusual | SEC |
| Jun 10, 2024 | Feller Faye | EVP, Chief Medical Officer | Form 4 sale | 287,900 | $1.3M | 100.0% | Unusual | SEC |
| Jun 10, 2024 | Kapur Anil | EVP, Corp Strategy & CCO | Form 4 sale | 421,875 | $2M | 100.0% | Unusual | SEC |
| Jun 4, 2024 | Scarlett John A | Chairman, President and CEO | Form 4 sale | 600,000 | $2.4M | 50.0% | Unusual | SEC |
| May 15, 2024 | Lawlis V Bryan | Director | Form 4 sale | 35,000 | $131k | 100.0% | Routine | SEC |
| May 11, 2023 | Lawlis V Bryan | Director | Form 144 notice | 35,000 | $105k | Notice | SEC | |
| May 11, 2023 | Lawlis V Bryan | Director | Form 4 sale | 35,000 | $105k | 100.0% | Routine | SEC |
| May 1, 2023 | Molineaux Susan | Director | Form 4 sale | 35,000 | $87k | 100.0% | Unusual | SEC |
| May 1, 2023 | Molineaux Susan | Director | Form 144 notice | 35,000 | $87k | Notice | SEC | |
| Feb 10, 2023 | Scarlett John A | Chairman, President and CEO | Form 4 sale | 1.3M | $4.1M | 100.0% | Unusual | SEC |
| Feb 9, 2023 | Grethlein Andrew J | EVP, Chief Operating Officer | Form 4 sale | 384,719 | $1.2M | 100.0% | Unusual | SEC |
| Feb 8, 2023 | Bloom Olivia Kyusuk | EVP, Chief Financial Officer | Form 4 sale | 400,000 | $1.2M | 84.3% | Unusual | SEC |
| Apr 9, 2019 | Behrs Melissa Kelly | EVP, Chief Business Officer | Form 4 sale | 120,635 | $241k | 100.0% | Unusual | SEC |
| Sep 13, 2018 | Spiegel Robert J. | Director | Form 4 sale | 175,000 | $1.2M | 72.7% | Unusual | SEC |
| Aug 24, 2018 | Rosenfield Stephen | EVP, Genl Counsel & Secretary | Form 4 sale | 1.4M | $6.1M | 100.0% | Unusual | SEC |
| May 29, 2015 | Bloom Olivia Kyusuk | EVP, Chief Financial Officer | Form 4 sale | 2,380 | $9k | 3.1% | Plan not stated | SEC |
| May 29, 2015 | Behrs Melissa Kelly | EVP BD and Port&Alliance Mgmt | Form 4 sale | 2,380 | $9k | 1.9% | Plan not stated | SEC |
| Mar 18, 2015 | Hofstaetter Thomas | Director | Form 4 sale | 70,000 | $287k | 72.5% | Unusual | SEC |
| May 29, 2014 | Bloom Olivia Kyusuk | EVP, Chief Financial Officer | Form 4 sale | 3,379 | $7k | 4.0% | Plan not stated | SEC |
| May 29, 2014 | Behrs Melissa Kelly | EVP Portfolio & Alliance Mgmt | Form 4 sale | 4,826 | $10k | 3.3% | Plan not stated | SEC |
| Apr 1, 2014 | Bloom Olivia Kyusuk | EVP, Chief Financial Officer | Form 4 sale | 7,435 | $16k | 8.0% | Plan not stated | SEC |
| Apr 1, 2014 | Behrs Melissa Kelly | EVP Portfolio & Alliance Mgmt | Form 4 sale | 12,310 | $26k | 7.7% | Plan not stated | SEC |
| Jan 17, 2013 | Behrs Melissa Kelly | SVP Alliance and Prog Mgmt | Form 4 sale | 28,292 | $47k | 100.0% | Unusual | SEC |
| May 30, 2012 | Kelsey Stephen Michael | EVP, R&D Head, CMO | Form 4 sale | 9,300 | $13k | 1.9% | Plan not stated | SEC |
| May 30, 2012 | Earp David | SVP, Corp Transactions | Form 4 sale | 27,155 | $37k | 5.5% | Plan not stated | SEC |
| May 30, 2012 | Bloom Olivia Kyusuk | VP, Chief Acctg Officer | Form 4 sale | 11,029 | $15k | 6.9% | Plan not stated | SEC |
| May 30, 2012 | Behrs Melissa Kelly | SVP Strategic Portfolio Mgmt | Form 4 sale | 18,910 | $26k | 4.5% | Plan not stated | SEC |
| Jun 14, 2011 | Spink Katharine E. | SVP Alliance Mgmt & Operations | Form 4 sale | 22,591 | $97k | 6.4% | Unusual | SEC |
| Jun 14, 2011 | Lebkowski Jane | SVP, Chief Scientific Officer | Form 4 sale | 25,262 | $108k | 4.3% | Unusual | SEC |
| Jun 14, 2011 | Kelsey Stephen Michael | EVP, R&D Head, CMO | Form 4 sale | 4,858 | $21k | 1.0% | Plan not stated | SEC |
| Jun 14, 2011 | Behrs Melissa Kelly | SVP Strategic Portfolio Mgmt | Form 4 sale | 25,262 | $108k | 5.6% | Unusual | SEC |
| Jun 14, 2011 | Greenwood David | President, Interim CEO, CFO | Form 4 sale | 34,005 | $146k | 4.3% | Unusual | SEC |
| Jun 14, 2011 | Earp David | Chief Legal Counsel | Form 4 sale | 25,262 | $108k | 4.9% | Unusual | SEC |
| Jun 14, 2011 | Bloom Olivia Kyusuk | VP, Chief Acctg Officer | Form 4 sale | 6,997 | $30k | 4.2% | Plan not stated | SEC |
| May 24, 2011 | Bloom Olivia Kyusuk | VP, Chief Acctg Officer | Form 4 sale | 1,200 | $5k | 0.7% | Plan not stated | SEC |
| May 24, 2011 | Spink Katharine E. | SVP Prgm Mgmt, Cell Therapies | Form 4 sale | 419 | $2k | 0.1% | Plan not stated | SEC |
| May 24, 2011 | Behrs Melissa Kelly | SVP Strategic Portfolio Mgmt | Form 4 sale | 2,975 | $13k | 0.7% | Plan not stated | SEC |
| May 24, 2011 | Earp David | SVP Bus Dev, Chief Patnt Couns | Form 4 sale | 2,975 | $13k | 0.6% | Plan not stated | SEC |
| May 24, 2011 | Lebkowski Jane | SVP, Chief Scientific Officer | Form 4 sale | 2,975 | $13k | 0.5% | Plan not stated | SEC |
| May 24, 2011 | Greenwood David | President, Interim CEO, CFO | Form 4 sale | 4,462 | $20k | 0.6% | Plan not stated | SEC |
| May 5, 2011 | Kelsey Stephen Michael | EVP, CMO, Oncology | Form 4 sale | 14,163 | $68k | 3.7% | Plan not stated | SEC |
| Jun 2, 2010 | Spink Katharine E. | VP Operations, Regen Med Progs | Form 4 sale | 8,186 | $44k | 8.2% | Unusual | SEC |
| Jun 2, 2010 | Lebkowski Jane | SVP, CSO Regen Med | Form 4 sale | 10,617 | $58k | 5.1% | Plan not stated | SEC |
| Jun 2, 2010 | Behrs Melissa Kelly | SVP Oncology | Form 4 sale | 10,617 | $58k | 7.2% | Plan not stated | SEC |
| Jun 2, 2010 | Earp David | SVP Bus Dev, Chief Patnt Couns | Form 4 sale | 10,617 | $58k | 5.0% | Plan not stated | SEC |
| Jun 2, 2010 | Greenwood David | EVP and CFO | Form 4 sale | 14,746 | $80k | 5.4% | Plan not stated | SEC |
| Jun 2, 2010 | Okarma Thomas | President and CEO | Form 4 sale | 18,874 | $102k | 4.1% | Plan not stated | SEC |
| May 24, 2010 | Spink Katharine E. | VP Operations, Regen Med Progs | Form 4 sale | 385 | $2k | 0.4% | Plan not stated | SEC |
| May 24, 2010 | Lebkowski Jane | SVP, CSO Regen Med | Form 4 sale | 2,336 | $12k | 1.1% | Plan not stated | SEC |
| May 24, 2010 | Behrs Melissa Kelly | SVP Oncology | Form 4 sale | 2,336 | $12k | 1.6% | Plan not stated | SEC |
| May 24, 2010 | Earp David | SVP Bus Dev, Chief Patnt Couns | Form 4 sale | 2,336 | $12k | 1.1% | Plan not stated | SEC |
| May 24, 2010 | Greenwood David | EVP and CFO | Form 4 sale | 3,503 | $18k | 1.3% | Plan not stated | SEC |
| May 24, 2010 | Okarma Thomas | President and CEO | Form 4 sale | 4,671 | $24k | 1.0% | Plan not stated | SEC |
| Apr 28, 2010 | Kelsey Stephen Michael | EVP, CMO, Oncology | Form 4 sale | 3,707 | $21k | 9.3% | Plan not stated | SEC |
| May 29, 2009 | Spink Katharine E. | VP Operations, Regen Med Progs | Form 4 sale | 400 | $3k | 3.8% | Plan not stated | SEC |
| May 29, 2009 | Okarma Thomas | President and CEO | Form 4 sale | 5,828 | $37k | 1.9% | Plan not stated | SEC |
| May 29, 2009 | Lebkowski Jane | SVP, CSO Regen Med | Form 4 sale | 2,277 | $14k | 1.9% | Plan not stated | SEC |
| May 29, 2009 | Behrs Melissa Kelly | SVP Oncology | Form 4 sale | 2,277 | $14k | 3.7% | Plan not stated | SEC |
| May 29, 2009 | Harley Calvin | VP, CSO Telomerase Tech | Form 4 sale | 2,277 | $14k | 3.2% | Plan not stated | SEC |
| May 29, 2009 | Earp David | SVP Bus Dev, Chief Patnt Couns | Form 4 sale | 2,277 | $14k | 1.8% | Plan not stated | SEC |
| May 29, 2009 | Greenwood David | EVP and CFO | Form 4 sale | 3,416 | $22k | 2.2% | Plan not stated | SEC |
| May 29, 2009 | Benedetti Fabio M | SVP, Chief Med Off, Oncology | Form 4 sale | 2,277 | $14k | 5.6% | Plan not stated | SEC |
| May 26, 2009 | Spink Katharine E. | VP Operations, Regen Med Progs | Form 4 sale | 2,864 | $19k | 21.4% | Plan not stated | SEC |
| May 26, 2009 | Okarma Thomas | President and CEO | Form 4 sale | 46,669 | $315k | 13.2% | Plan not stated | SEC |
| May 26, 2009 | Behrs Melissa Kelly | SVP Oncology | Form 4 sale | 6,819 | $46k | 10.0% | Plan not stated | SEC |
| May 26, 2009 | Lebkowski Jane | SVP, CSO Regen Med | Form 4 sale | 14,092 | $95k | 10.3% | Plan not stated | SEC |
| May 26, 2009 | Harley Calvin | VP, CSO Telomerase Tech | Form 4 sale | 10,001 | $68k | 12.3% | Plan not stated | SEC |
| May 26, 2009 | Greenwood David | EVP and CFO | Form 4 sale | 19,320 | $130k | 11.0% | Plan not stated | SEC |
| May 26, 2009 | Earp David | SVP Bus Dev, Chief Patnt Couns | Form 4 sale | 15,456 | $104k | 10.7% | Plan not stated | SEC |
| Apr 3, 2009 | Benedetti Fabio M | SVP, Chief Med Off, Oncology | Form 4 sale | 5,195 | $23k | 11.4% | Plan not stated | SEC |
| Feb 2, 2009 | Behrs Melissa Kelly | SVP Oncology | Form 4 sale | 14,765 | $120k | 100.0% | Unusual | SEC |
| Jan 30, 2009 | Walker John Peter | Director | Form 4 sale | 48,617 | $403k | 55.4% | Unusual | SEC |
| Jan 29, 2009 | Harley Calvin | VP and CSO | Form 4 sale | 30,489 | $216k | 23.5% | Unusual | SEC |
| Jan 5, 2009 | Okarma Thomas | President and CEO | Form 4 sale | 12,512 | $61k | 3.4% | Plan not stated | SEC |
| Jan 5, 2009 | Lebkowski Jane | SVP Regen Medicine | Form 4 sale | 8,861 | $43k | 5.6% | Plan not stated | SEC |
| Jan 5, 2009 | Behrs Melissa Kelly | SVP Oncology | Form 4 sale | 8,861 | $43k | 10.0% | Plan not stated | SEC |
| Jan 5, 2009 | Harley Calvin | VP and CSO | Form 4 sale | 8,861 | $43k | 6.6% | Plan not stated | SEC |
| Jan 5, 2009 | Greenwood David | EVP and CFO | Form 4 sale | 10,732 | $53k | 5.6% | Plan not stated | SEC |
| Jan 5, 2009 | Earp David | SVP Bus Dev, Chief Patnt Couns | Form 4 sale | 8,861 | $43k | 5.4% | Plan not stated | SEC |
| Nov 5, 2008 | Behrs Melissa Kelly | SVP Oncology | Form 4 sale | 23,845 | $97k | 21.2% | Plan not stated | SEC |
| Jan 4, 2008 | Okarma Thomas | President and CEO | Form 4 sale | 13,166 | $70k | 3.5% | Plan not stated | SEC |
| Jan 4, 2008 | Lebkowski Jane | SVP Regen Medicine | Form 4 sale | 8,911 | $48k | 5.7% | Plan not stated | SEC |
| Jan 4, 2008 | Behrs Melissa Kelly | SVP Oncology | Form 4 sale | 8,911 | $48k | 8.6% | Plan not stated | SEC |
| Jan 4, 2008 | Harley Calvin | VP and CSO | Form 4 sale | 8,911 | $48k | 6.9% | Plan not stated | SEC |
| Jan 4, 2008 | Greenwood David | EVP and CFO | Form 4 sale | 11,039 | $59k | 6.0% | Plan not stated | SEC |
| Jan 4, 2008 | Earp David | SVP Bus Dev, Chief Patnt Couns | Form 4 sale | 8,911 | $48k | 5.4% | Plan not stated | SEC |
| Nov 12, 2007 | Greenwood David | EVP and CFO | Form 4 sale | 4,000 | $29k | 2.2% | Plan not stated | SEC |
| May 18, 2007 | Harley Calvin | VP and CSO | Form 4 sale | 30,000 | $276k | 34.4% | Unusual | SEC |
| Jan 9, 2006 | Behrs Melissa Kelly | VP, Oncology | Form 4 sale | 8,441 | $72k | 53.4% | Unusual | SEC |
| Jan 9, 2006 | Lebkowski Jane | SVP, Regenerative Medicine | Form 4 sale | 10,676 | $91k | 35.7% | Unusual | SEC |
| Jan 9, 2006 | Okarma Thomas | President and CEO | Form 4 sale | 12,320 | $105k | 28.1% | Unusual | SEC |
| Jan 9, 2006 | Harley Calvin | Chief Scientific Officer | Form 4 sale | 9,183 | $79k | 53.3% | Unusual | SEC |
| Jan 9, 2006 | Greenwood David | Executive VP and CFO | Form 4 sale | 12,183 | $104k | 41.8% | Unusual | SEC |
| Jan 9, 2006 | Earp David | SVP Bus Dev / Chf Patent Couns | Form 4 sale | 11,323 | $97k | 35.7% | Unusual | SEC |